Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193401
Status:
COMPLETED
Last Update Posted:
2010-07-28
First Post:
2005-09-12
Brief Title:
Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase II Trial of Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this phase II trial we will evaluate the weekly schedule of topotecan in the first-line treatment of elderly andor poor performance status patients with extensive stage small cell lung cancer Patients eligible for this trial will be those considered poor candidates for standard combination chemotherapy or other investigational regimens
Detailed Description:
Upon determination of eligibility all patients will be receive
Topotecan
Topotecan
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 104864665 | None | None | None |